Nabi Biopharmaceuticals (NABI)

Company

"Nabi Biopharmaceuticals leverages its experience and knowledge in powering the immune system to develop and market products that fight serious medical conditions. The Company is focusing on developing products addressing commercial opportunities in its core business areas: Gram-positive bacterial infections, hepatitis, kidney disease (nephrology), and nicotine addiction. There are three products on the market today: PhosLo® (calcium acetate), Nabi-HB® [Hepatitis B Immune Globulin (Human)], and Aloprim™ (allopurinol sodium) for Injection and a number of products in various stages of clinical and preclinical development." (company website)

Buy

12-Apr-06. NABI has been bumping along sidewise for a couple of weeks and there are early signs to pin hopes on, specifically an uptick in relative strength (RSI) and in the more-sensitive stochastic RSI.

• Price momentum (PPO) — falling off slightly
• Trend (ADX) — trend is stable with buying pressure (+DI) still well above selling pressure (-DI)
• Money flow (CMF) — still positive, although falling off a bit
• Relative strength (RSI) — ticking up, along with stochastic RSI
• Volume — huge volume on jump above $5.50

Sell

25-Apr-06. After a spirited debate with myself — "Sell." "No, hold." "Sell." "Hold." — I sold my NABI this morning. While there is nothing very alarming in the chart, there are suggestions that NABI is either going to consolidate for a while or touch back to the moving averages: momentum (PPO) has slacked off; buying pressure (+DI) has dipped; and relative strength (RSI) has eased. At this point, the lower Bollinger band is above the 50-day moving average — quite a ways ahead of the game. Also, this is the fourth consecutive day of declines.

Better to take a few dollars to the bank than put modest profits at risk.